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INTRODUCTION/BACKGROUND
Antibodies are composed of four chains: two identical 
light chains of DNA and two identical heavy chains of 
DNA. The Fc fragment is the lower lobe of the antibody, 
and is attached to the two upper lobes, where antigen 
binding occurs, by a hinge region, as shown in Figure 
1. The binding of effector molecules to the Fc region 
leads to an immune response within the body. Sugars 
within the Fc fragment help give structure to this region, 
presumably allowing effector molecules to more readily 
bind to this region, resulting in an immune response. 
When these sugars are removed, the Fc fragment is only 
supported by the hinge region, allowing the lobe to move 
freely, thereby reducing the binding affinity of effector 
molecules, such as Fc receptors.1
 
The particular sugars present within the Fc region do not 
always maximize the binding ability of the Fc region. The 
precise nature of the sugar molecules present in the Fc 
region has been shown to impact the binding of effector 
molecules,2,3 leading to a desire to develop therapeutic 
antibodies containing sugars that best promote effector 
molecule binding.  Scientists have been tediously 
working to develop therapeutic antibodies, or antibodies 
used for treatment of diseases, containing sugars within 
the Fc region that increase the binding affinity of the 
antibodies for effector molecules.2-4 This process, 
known as glycoengineering, is not only time consuming, 
but also very expensive, as proteins containing sugars 
must be produced in mammalian cells. By developing a 
way to keep the Fc region stable and receptive to effector 
molecules without the need for glycoengineering or 
the use of mammalian cells, the tedious process of 
glycoengineering could be avoided.
A cheaper alternative to protein synthesis is expressing 
antibodies in E. coli, however, antibodies synthesized in 
E. coli do not have the sugars thought to be necessary 
for maximal binding of effector molecules. By mutating 
the amino acids present at the bottom tip of the Fc 
fragment (see Figure 4), Jung et al. have been able to 
stabilize the Fc region of IgG and achieve binding to 
A B S T R A C T Humanized antibody plasmid DNA was modified to allow the distance between the Fc fragment and 
antigen binding sites of immunoglobulin G (IgG) antibodies to be studied. Specific variable heavy (VH) and variable 
light (VL) genes were inserted into heavy and light chain plasmids so that dye molecules can be easily attached to the 
expressed protein, and further inspection of antibody structure and function can be conducted via single molecule 
Förster resonance energy transfer (FRET). First, VH and VL genes were inserted into humanized antibody plasmids 
through the technique of ligation. The ligation product was then transformed into Escherichia coli cells, allowing the 
success of the ligation reaction to be determined by methods of agarose gel electrophoresis and sequencing of the 
plasmid DNA.
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effector molecules at a level similar to that observed 
in naturally occurring IgG.4 It is believed that because 
the mutations are so far from the binding sites for the 
effector molecules, a conformational change is occurring 
within the Fc region, so that it takes on a conformation 
similar to that of the Fc region when it contains sugars 
(Figure 4).4  By synthesizing these sugar free antibodies 
in E. coli, it may be possible to develop a cheaper route 
to therapeutic antibodies. While it has been suggested 
that the tight binding of the mutated protein arises from 
a conformational change, this has not been confirmed 
with structural studies. The structures of these mutated 
antibodies with and without the sugars present must be 
further examined. 
One technique that can be used to do this is Förster 
resonance energy transfer (FRET). FRET can be used to 
examine the structure of the Fc region with and without 
the mutations introduced and with and without the sugar 
molecules present. FRET is also capable of determining 
the flexibility of a protein, as well as determining the 
number of conformations of a protein present. The 
technique involves placing a donor and an acceptor 
dye molecule on a protein. The donor absorbs light and 
can transfer this energy to the acceptor. The closer the 
acceptor is to the donor, the more likely it is that energy 
transfer will occur. By examining the relative amounts 
of fluorescence from the donor and the acceptor, the 
distance between the two can be calculated.  In addition, 
the distance between the antigen binding sites and the 
Fc region is of interest, as it has been suggested that the 
Fc region curls up toward the antigen binding site to 
promote the binding of effector molecules
In order to attach a dye molecule to the antigen binding 
site, the DNA for the antigen binding site of a humanized 
(containing both human and mouse parts) IgG antibody 
was modified.  This modification process was the goal of 
this research project.
EXPERIMENTAL
VL and the VH genes from the plasmids for the 
humanized antibody (see Figures 5 and 6) were cut and 
removed using restriction enzymes (HindIII and BamHI) 
and replaced with the VL and VH regions from a mouse 
antibody through the process of ligation. (see Figure 
7) The VL and VH regions from the mouse antibody 
are desirable because they will produce a new antigen 
binding site on the Fc region, containing a reactive lysine 
residue, which is necessary for dye attachment. 
The ligation products were then introduced into E. coli 
cells. By introducing the plasmid into E. coli cells, the 
DNA can be replicated as the cells divide and grow 
overnight.  The DNA in any colonies observed was then 
isolated and examined to see if the ligation reaction was 
successful. 
To see if the ligation reactions were successful, the 
polymerase chain reaction (PCR) was used to amplify the 
VL and VH regions that should be in the ligated plasmid 
DNA.  In addition, restriction digests were used to cut out 
the VL and VH genes. The PCR products and restriction 
digest fragments were isolated, cleaned, and run on an 
agarose gel. An agarose gel separates substances by 
molecular weight. By running the different fragments 
and knowing how many base pairs each gene has, it is 
possible to tell if the reaction worked based on how far 
the bands are visualized down the gel. (see Figure 8). If 
the ligation was successful, bands should be visualized 
around 360bp.  Single cut plasmid and uncut plasmid 
were also run on the gel for control samples. 
 
The ligation and PCR reactions for the VL and the VH 
genes were performed separately. Gel results for the VH 
chain suggested that the ligation product was produced, 
while the gel results for the VL chain (data not shown) 
were inconclusive. A sample of the VH chain was then 
prepared and sent to Macrogen for sequencing. Because 
the desired DNA sequence is known, the sequencing 
results received from Macrogen could be compared to 
the desired sequence using CLC Sequence Viewer 6. 
Sequencing confirmed the PCR results, indicating that 
the ligation reaction was successful.
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CONCLUSION
The VL and VH plasmids were ligated and analyzed 
several times. The VH ligation was determined to be 
a success by the agarose gel and sequencing results, 
whereas the VL ligation products were inconclusive from 
the agarose gel and therefore not sent out for sequencing. 
It is believed that because the VL plasmid contains 
a significantly larger number of base pairs than the 
VL insert, the ligase enzyme responsible for finding 
and connecting the vector and insert was unable to 
find the two vectors to combine them, and the ligation 
reaction did not proceed. Different techniques were 
incorporated into each new reaction, however, further 
troubleshooting throughout the entire ligation process 
proved unsuccessful. By successfully inserting the VH 
vector into the plasmid DNA of an IgG antibody, the 
dye molecule can be attached and FRET can be used 
to further understand the structure of the Fc region of 
antibodies for future therapeutic applications.
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ability of the Fc region. The precise nature of the sugar molecules present in the Fc region has 
been shown to impact the binding of effector molecules,2,3 leading to a desire to develop 
therapeutic antibodies containing sugars that best promote effector molecule binding.  Scientists 
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Figure 1: Crystal structure of an IgG 
antibody. The Fc region is attached to the two 
upper lobes by the hinge region.  Antibody 
drawn from the PDB file 1IGT. Harris, 
L.J.; Larson, S.B.; Hasel, K.W.; McPherson, 
A. (1997) Biochemistry 36, 1581. 
Figure 2: Schematic of an IgG 
antibody showing the locations 
at which various effector 
molecules bind. 
Figure 3: Crystal structure of 
human FcgRIII (green) bound 
to a human IgG Fc region (blue 
and purple).  The binding 
occurs in the lower hinge and 
upper CH2 regions. Drawn from 
the PDB file 1E4K. 
6Sondermann, P.; Huber, R.; 
Oosthuizen, V.; Jacob, U. 
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Crystal structure of an IgG antibody. The Fc region is attached to 
the two upper lobes by the hinge region.  Antibody drawn from the 
PDB file 1IGT. Harris, L.J.; Larson, S.B.; Hasel, K.W.; McPherson, A. 
(1997) Biochemistry 36, 1581.
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2: Schematic of an IgG antibody showing the locations at which 
various effector molecules bind.
3: Crystal structure of human FcγRIII (green) bound to a human 
IgG Fc region (blue and purple).  The binding occurs in the lower 
hinge and upper CH2 regions. Drawn from th  PDB file 1E4K. 
6Sondermann, P.; Huber, R.; Oosthuizen, V.; Jacob, U. (2000) 
Nature 406, 267.
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Figure 4: (a) Glycosylated 
IgG1 antibody showing a fixed 
confirmation (b) Aglycosylated 
IgG1 antibody showing high 
flexible conformations. (c) 
Engineered aglycosylated IgG1 
antibody showing a fixed 
confirmations. Jung ST, Kang 
TH, Kelton W, Georgiou G. 
Curr. Opin. Che, Biol. 2011, 
22, 858-867. 
of diseases, containing sugars within the Fc region that increase 
the binding affinity of the antibodies for effector molecules.2-4 
This process, known as glycoengineering, is not only time 
consuming, but also very expensive, as proteins containing 
sugars must be produced in mammalian cells. By developing a 
way to keep the Fc region stable and receptive to effector 
molecules without the need for glycoengineering or the use of 
mammalian cells, the tedious process of glycoengineering could 
be avoided. 
 A cheaper alternative to protein synthesis is 
expressing antibodies in E. coli, however, antibodies synthesized 
in E. coli do not have the sugars thought to be necessary for 
maximal binding of effector molecules. By mutating the amino 
acids present at the bottom tip of the Fc fragment (see Figure 4), 
Jung et al. have been able to stabilize the Fc region of IgG and achieve binding to effector 
molecules at a level similar to that observed in naturally occurring IgG.4 It is believed that 
because the mutations are so far from the binding sites for the 
effector molecules, a conformational change is occurring within 
the Fc region, so that it takes on a conformation similar to that of 
the Fc region when it contains sugars (Figure 4).4  By synthesizing 
these sugar free antibodies in E. coli, it may be possible to develop 
a cheaper route to therapeutic antibodies. While it has been 






Figure 7: Schematic showing the process used to alter the VH (or VL) gene of an antibody. 
 
Figure 5: Plasmid map for the heavy 
chain of the humanized antibody 
showing the locations of the HindIII 
and BamHI restriction enzyme cut sites 
at either end of the VH gene.  The 
locations of other genes for the heavy 
chain (CH1, hinge, CH2, and CH3) and 
the ampicillin resistance gene are also 
shown.  
	  
Figure 6: Plasmid map for the light 
chain of the humanized a tibody 
showing the locations of the HindIII 
and BamHI restriction enzyme cut 
sites at either end of the VL ge e.  
The Ck and ampicillin resitance 
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Plasmid map for the heavy chain of the humanized antibody showing 
the locations of the HindIII and BamHI restriction enzyme cut 
sites at either end of the VH gene.  The locations of other genes for 
the heavy chain (CH1, hinge, CH2, and CH3) and the ampicillin 
resistance gene are also shown. 
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Plasmid map for the light chain of the humanized antibody showing 
the locations of the HindIII and BamHI restriction enzyme cut sites 
at either end of the VL gene.  The Ck and ampicillin resitance genes 
are also shown. 
FIGURE 6
 
(a) Glycosylated IgG1 antibody showing a fixed confirmation  
(b) Aglycosylated IgG1 antibody showing high flexible conformations.  
(c) Engineered aglycosylated IgG1 antibody showing a fixed confirmations. 
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The ligation products were then introduced into E. coli cells. By introducing the plasmid into E. 
coli cells, the DNA can be replicated as the cells divide and grow overnight.  The DNA in any 
colonies observed was then isolated and examined to see if the ligation reaction was successful.  
To see if the ligation reactions were successful, the polymerase chain reaction (PCR) was 
used to amplify the VL and VH regions that should be in the ligated plasmid DNA.  In addition, 
restriction digests were used to cut out the VL and VH genes. The PCR products and restriction 
digest fragments were isolated, cleaned, and run on an agarose gel. An agarose gel separates 
substances by molecular weight. By running the different fragments and knowing how many 
base pairs each gene has, it is possible to tell if the reaction worked based on how far the bands 
are visualized down the gel. (see Figure 8). If the ligation was successful, bands should be 
visualized around 360bp.  Single cut plasmid and uncut plasmid were also run on the gel for 
control samples.  
 
 
Figure 8: Stained agarose gel 
of the variable heavy chain 
from the VH36/aLys-28 
plasmid. Lanes 1-4 represent 
the double cut variable chain 
region. Lane 6 represents the 
double digest of the VH 
fragment from the plasmid. 
Lane 7 is the single cut 
plasmid, and Lane 8 represents 







Figure 7: Schematic showing the process used to alter the VH (or VL) gene of an antibody. 
 
Figure 5: Plasmid map for the heavy 
chain of the humanized antibody 
showing the locations of the HindIII 
and BamHI restriction enzyme cut sites 
at either end of the VH gene.  The 
locations of other genes for the heavy 
chain (CH1, hinge, CH2, and CH3) and 
the ampicillin resistance gene are also 
shown.  
	  
Figure 6: Plasmid map for the light 
chain of the humanized antibody 
showing the locations of the HindIII 
and BamHI restriction enzyme cut 
sites at either end of the VL gene.  
The Ck and ampicillin resitance 
genes are also shown.  
 




Stained agarose gel of the variable heavy chain from the VH36/
aLys-28 plasmid. Lanes 1-4 represent the double cut variable chain 
region. Lane 6 represents the double digest of the VH fragment from 
the plasmid. Lane 7 is the single cut plasmid, and Lane 8 represents 
the uncut plasmid. 
FIGURE 8
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